Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial

Infinitopes’ lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, “off-the-shelf” cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancers Infinitopes’ proprietary vector delivery…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.